Sangenito Leandro S, Branquinha Marta H, Santos André L S
Laboratório de Estudos Avançados de Microrganismos Emergentes e Resistentes (LEAMER), Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro 21941-901, Brazil.
Programa de Pós-Graduação em Bioquímica (PPGBq), Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Trop Med Infect Dis. 2020 Jun 1;5(2):88. doi: 10.3390/tropicalmed5020088.
Chagas disease was discovered in 1909 by the Brazilian scientist Carlos Chagas. After more than 110 years, many outcomes have been achieved in all research fields; however, Chagas disease remains a serious public health problem, mainly in Latin America, being one of the most neglected tropical diseases in the world. As a neglected disease, it receives very little financial support. Nevertheless, how much is actually spent? With this question in mind, the goal of the present work was to summarize all funding employed by multiple institutions in the Chagas disease field in a 10-year survey. From 2009 to 2018, Chagas disease received only USD 236.31 million, representing 0.67% of the total applied for all neglected diseases in this period. Mostly, the investments are concentrated in basic research (47%) and drug development (42.5%), with the public sector responsible for 74% of all funding, followed by the industry (19%) and philanthropy (7%). Relevantly, NIH (USA) alone accounted for more than half of the total investment. Taking into account that Chagas disease has a great socio-economic impact, it is clear that more investments are needed, especially from endemic countries. Furthermore, coordinated strategies to make better use of resources and incentives for the pharmaceutical industry must be adopted.
恰加斯病于1909年由巴西科学家卡洛斯·恰加斯发现。110多年后，各个研究领域都取得了许多成果；然而，恰加斯病仍然是一个严重的公共卫生问题，主要在拉丁美洲，它是世界上最被忽视的热带疾病之一。作为一种被忽视的疾病，它获得的资金支持极少。然而，实际花费了多少呢？带着这个问题，本研究的目的是总结在一项为期10年的调查中多个机构在恰加斯病领域所使用的所有资金。2009年至2018年期间，恰加斯病仅获得了2.3631亿美元，占该时期所有被忽视疾病申请资金总额的0.67%。大部分投资集中在基础研究（47%）和药物开发（42.5%），公共部门负责所有资金的74%，其次是行业（19%）和慈善机构（7%）。值得注意的是，仅美国国立卫生研究院（NIH）就占总投资的一半以上。考虑到恰加斯病具有巨大的社会经济影响，显然需要更多投资，特别是来自流行国家的投资。此外，必须采取协调战略，以更好地利用资源并激励制药行业。
